Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Common Equity: 2018-2021

  • Genmab A's Common Equity rose 30.33% to $2,405 in Q2 2021 from the same period last year, while for Jun 2021 it was $2,405, marking a year-over-year increase of 30.33%. This contributed to the annual value of $2.2 billion for FY2020, which is 52.05% up from last year.
  • Latest data reveals that Genmab A reported Common Equity of $2,405 as of Q2 2021, which was down 100.00% from $2.2 billion recorded in Q4 2020.
  • In the past 5 years, Genmab A's Common Equity registered a high of $2.2 billion during Q4 2020, and its lowest value of $1,845 during Q2 2020.
  • Its 3-year average for Common Equity is $912.0 million, with a median of $877.8 million in 2019.
  • Per our database at Business Quant, Genmab A's Common Equity soared by 64.87% in 2019 and then tumbled by 100.00% in 2020.
  • Over the past 4 years, Genmab A's Common Equity (Quarterly) stood at $886.1 million in 2018, then surged by 64.87% to $1.5 billion in 2019, then skyrocketed by 52.05% to $2.2 billion in 2020, then spiked by 30.33% to $2,405 in 2021.
  • Its Common Equity stands at $2,405 for Q2 2021, versus $2.2 billion for Q4 2020 and $1,845 for Q2 2020.